ArticlePloS one2026
Network of interactions between the tumor necrosis factor superfamily members and small S100 proteins.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor Necrosis Factor Superfamily (TNFSF) comprises 20 members of membrane/soluble signaling proteins regulating cell survival, cell proliferation/differentiation, and innate/adaptive immunity. Targeting signaling of TNFSF members is used clinically to treat several autoimmune and oncological diseases, and bone loss. They and their cognate receptors are in clinical trials as targets for treatment of autoimmune, inflammatory, oncological and other diseases. Recently, some representatives of S100 family of pleiotropic calcium-binding proteins were shown to interact with TNFSF members TNF and TRAIL, thereby suppressing their activity. In this work, we explored selectivity of interactions between soluble forms of 13 TNFSF members and 21 non-fused S100 proteins using surface plasmon resonance spectroscopy. A total of 27 interactions were found between CD70, CD30L, 4-1BBL, TWEAK, APRIL, LIGHT, VEGI and AITRL and Ca2+-loaded forms of S100A1/A2/A4/A5/A6/A12/A16/B/P proteins, with equilibrium dissociation constants from 2 nM to 24 μM. Removal of calcium leads to disruption of the interactions. Molecular docking indicates presence of well-conserved binding sites of the both interaction partners. Mutagenesis of S100P evidences involvement of its 'hinge' region in binding of CD30L, VEGI and AITRL, as well as F89 residue in VEGI recognition. The revealed network of interactions is potentially important for regulation of the cellular communication mediated by TNFSF/S100 proteins, which could be exploited for targeted therapy of socially significant diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.